Ultragenyx Pharmaceutical Inc.
Ultragenyx Fights for Cures Amid Rising R&D Costs - NAM
DOJ Civil Division on X: "Pharmaceutical Company Ultragenyx Agrees to Pay $6 Million for Allegedly Paying Kickbacks to Induce Claims for Its Drug Crysvita https://t.co/Zx3qbY0FcH https://t.co/qhCWcKvyDM" / X
Ultragenyx Overview | SignalHire Company Profile
Press Release
Events & presentations—Ultragenyx Pharmaceutical Inc.
Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology | World Pharma Today
Ultragenyx Pharmaceutical Development Pipeline – Angelman Syndrome Foundation
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy - CureDuchenne
Ultragenyx: Outstanding Q4 2018 Results (NASDAQ:RARE) | Seeking Alpha
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharmaceutical to Distribute DOJOLVI™ (triheptanoin), for Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) - PANTHERx Rare
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Announces Proposed Public Offering of Common Stock | RARE Stock News
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy - Jett Foundation
Update from Dr. Alison Skrinar on the Ultragenyx trials, Orbit and Cosmic – OI Foundation
Marin County's Ultragenyx Pharmaceutical estimates sales grew nearly 20% in 2023
Events & presentations—Ultragenyx Pharmaceutical Inc.
Ultragenyx en LinkedIn: #raredisease
Ultragenyx's Corporate Sustainability Journey—Ultragenyx
Ultragenyx Signs a License Agreement with Mereo for Setrusumab in Osteogenesis Imperfecta
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES SALE OF ITS SHARES IN GENETX TO ULTRAGENYX
Press releases—Ultragenyx Pharmaceutical Inc.
Articles about Ultragenyx Pharmaceutical Inc.
